Precision BioSciences Inc
DTIL
NASDAQ
Biotechnology
$7.43
USD
+0.13 (+1.78%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $200.39M
Volume 142.1K
Revenue
—
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
—
TTM
— YoY
Operating Cash Flow
—
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q3 2026 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 34.2 | — | 0.0 |
YoY Growth | -100.0% | -97.7% | +5261.1% | — | -37.9% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | — | 0.0 |
Gross Profit | 0.0 | 0.0 | 34.2 | — | 0.0 |
Selling, General & Administrative | 9.1 | 7.3 | 7.2 | — | 9.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | — | 0.0 |
Total Operating Expenses | 21.9 | 20.7 | 21.7 | — | 21.9 |
Operating Income | -21.9 | -20.7 | 12.5 | — | -21.9 |
EBITDA | -21.5 | -20.3 | 12.9 | — | -21.9 |
Other Income / Expense | -2.4 | -1.8 | 6.3 | — | -2.4 |
Total Other Income / Expense | -1.6 | -1.1 | 6.7 | — | -1.6 |
Income Before Income Taxes | -23.5 | -21.8 | 19.2 | — | -23.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | — | 0.0 |
Net Income | -23.5 | -21.8 | 20.1 | — | -18.4 |
Consolidated Net Income / Loss | -23.5 | -21.8 | 20.1 | — | -23.5 |
Net Income Attributable to Common Shareholders | -23.5 | -21.8 | 20.1 | — | -23.5 |
Basic EPS | -$2.13 | -$1.84 | $1.05 | — | -$2.13 |
Diluted EPS | -$2.13 | -$1.84 | $1.05 | — | -$2.13 |
Basic Shares Outstanding | 11.0M | 11.8M | 19.1M | — | 11.0M |
Diluted Shares Outstanding | 11.0M | 11.8M | 19.1M | — | 11.0M |